Related Experiment Videos
Gynaecologic effects of tamoxifen
1Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Medical Oncology (Northwood, London, England)
|June 1, 1995
Summary
Tamoxifen is a breast cancer treatment that helps survival but can affect reproductive tissues. This review examines its specific gynecologic effects, including increased uterine cancer risk.
Area of Science:
- Oncology
- Gynecology
- Pharmacology
Background:
- Tamoxifen is a key adjuvant therapy for breast cancer, improving survival and reducing recurrence.
- Its therapeutic benefits are established in numerous clinical studies.
- However, tamoxifen exhibits tissue-specific effects, acting as an estrogen agonist in certain gynecologic tissues.
Purpose of the Study:
- To review the known gynecologic effects of tamoxifen.
- To highlight the estrogenic (agonist) effects on the endometrium, myometrium, and vagina.
- To discuss the clinical implications, particularly the increased risk of uterine cancer.
Main Methods:
- Literature review of European and American studies.
- Analysis of placebo-controlled clinical trials.
- Synthesis of data on tamoxifen's tissue-specific actions and clinical outcomes.
Main Results:
- Tamoxifen demonstrates significant efficacy in breast cancer treatment.
- Estrogenic effects are observed in the endometrium, myometrium, and vagina.
- Placebo-controlled trials confirm an increased incidence of uterine cancer associated with tamoxifen use.
Conclusions:
- Tamoxifen's widespread use necessitates a thorough understanding of its gynecologic side effects.
- The estrogen agonist activity in reproductive tissues is a critical consideration.
- Monitoring for and managing gynecologic adverse events, especially uterine cancer, is essential for patients on tamoxifen therapy.